Search results
Results from the WOW.Com Content Network
Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, or as part of transgender hormone therapy.
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
[3] [4] It is a decapeptide (pGlu-His-Trp-Ser-Tyr- D -Trp-Leu-Arg-Pro-Gly-NH 2 ) and a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts . Primary indications include endometriosis , [ 5 ] for the reduction of uterine fibroids , to treat prostate cancer , and to treat male hypersexuality with severe ...
Participants were mainly white (66%), male (78%), middle aged (median 63.8 +/- 11 years) with NYHA stage II (71.6%) or stage III (23.1%) heart failure. [ 46 ] The trial was stopped early after a prespecified interim analysis revealed a reduction in the primary endpoint of cardiovascular death or heart failure in the sacubitril/valsartan group ...
Venetoclax is a BH3-mimetic. [11] Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has been linked to increased resistance to chemotherapy.
Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. [10] It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC).
More current studies, however, have failed to show a positive association between use of acepromazine and seizure activity [9]: 116 [16] and show a possible role for acepromazine in seizure control: in a retrospective study at University of Tennessee, acepromazine was administered for tranquilization to 36 dogs with a prior history of seizures ...
Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. Mirabegron was approved for medical use in the United States and in the European Union in 2012. [8] [9] [3] In 2022, it was the 222nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.